Salih, Teresita T.

HRN: 21-53-95  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/06/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/06/2022
08/12/2022
IV
100mg
Q24
CAP HR
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Pneumonia    Compliance to guidelines: Guideline Not Available

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: